Anti-ADDL antibodies and uses thereof

• US 20030068316A1
• Filed: 06/11/2002
• Published: 04/10/2003
• Est. Priority Date: 02/05/1997
• Status: Abandoned Application

• Current Assignee: Brett A. Chromy, Caleb E. Finch, Chang Lei, Grant A Krafft, Irina Rozofsky, Kirsten L. Viola, Mary P Lambert, Todd E. Morgan, William L. Klein, Yue Song Gong
• Original Assignee: Brett A. Chromy, Caleb E. Finch, Chang Lei, Grant A Krafft, Irina Rozofsky, Kirsten L. Viola, Mary P Lambert, Todd E. Morgan, William L. Klein, Yue Song Gong
• Inventors: Chromy, Brett A., Gong, Yue Song, Rozofsky, Irina, Morgan, Todd E., Lambert, Mary P., Krafft, Grant A., Klein, William L., Chang, Lei, Finch, Caleb E., Viola, Kirsten L.
• Application Number:
  US10/166,856
• Publication Number:
  US 20030068316A1
• Time in Patent Office: Days
• US Class Current: 424/130.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: C07K 14/4711 Alzheimer's disease; Amyloid plaque core protein
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: G01N 2333/4709 Amyloid plaque core protein
• CPC Class Codes: G01N 2800/2821 Alzheimer
• CPC Class Codes: G01N 33/6896 Neurological disorders, e.g. Alzheimer's disease

Abstract

The invention herein comprises antibodies that bind to amyloid beta-derived diffusible ligands (ADDLs). ADDLs comprise amyloid β protein assembled into soluble, globular, non-fibrillar, oligomeric structures capable of activating specific cellular processes. The invention also comprises methods of using ADDL-specific antibodies for assaying the formation, presence, receptor protein binding and cellular activity of ADDLs, as well as using such antibodies to detect compounds that block the formation or activity of ADDLs, and methods of identifying such compounds. The invention further provides methods of using ADDL-specific antibodies in modulating ADDL formation and/or activity, inter alia in the treatment of learning and/or memory disorders.

Claims

1. A composition comprising one or more antibodies that interacts preferentially with soluble, non-fibrillar oligomeric assemblies of amyloid β

protein.

2. A composition as in claim 1, wherein the assemblies are ADDLs.

3. A composition as in either of claim 1 or claim 2, wherein the one or more antibodies are M90, M93 or M94 antibodies.

12. Any composition of claims 1-11, wherein the ADDL binding site is incorporated into a human antibody framework.

13. A method for detecting, in fluid taken from a patient, the presence of soluble, non-fibrillar assemblies of amyloid β

protein, the method comprising contacting the fluid with the composition as in any one of claims 1-12 and determining the presence of the assemblies.

14. A method for detecting, in tissue taken from a patient, the presence of soluble, non-fibrillar assemblies of amyloid β

protein, the method comprising homogenizing the tissue, extracting the tissue with a buffer, contacting the buffer with the composition as in any one of claims 1-12 and determining the presence of the assemblies.

15. A method for counteracting the effects of soluble, non-fibrillar assemblies of amyloid β

protein, the method comprising administering the composition as in any one of claims 1-12 to a patient in need of such treatment.

16. A method for detecting the presence of molecules that interfere with the formation of soluble, non-fibrillar assemblies of amyloid β

protein, the method comprising contacting any composition of claims 1-12 with a solution of Ab 1-42 incubated in the presence of test molecules under conditions known to form ADDLs, and determining by dot blot or other methods whether ADDLs are present.

17. A method for detecting the presence of molecules that interfere with the binding of soluble, non-fibrillar assemblies of amyloid 1 protein to specific ADDL receptors on neurons, the method comprising incubation of one or more test compounds with a blot of nerve cell membrane proteins, followed by incubation of the blot with a solution containing ADDLs, followed by washing and contacting the blot with any composition of claims 1-12 to whether the test molecule blocked the binding of ADDLs to the blotted proteins.

18. The method of claim 17 wherein the ADDL receptors have molecular weights of approximately 140 kDa and 260 kDa.

4. A composition comprising one or more antibodies that bind preferentially to soluble, globular, non-fibrillar protein assemblies of amyloid β

_1-42.

5. A composition as in claim 4, wherein the assemblies are ADDLs.

6. A composition as in either of claim 4 or 5, wherein the antibodies are the M90, M93 or M94 antibodies.

7. A composition comprising antibodies that bind preferentially to amyloid β

-derived diffusible ligands (ADDLs).

8. A composition as in claim 7, wherein the antibodies are the M90, M93 or M94 antibodies.

9. A composition comprising one or more antibody binding sites that bind preferentially to ADDLs.

10. A composition comprising one or more modified antibody binding sites that bind preferentially to ADDLs.

11. A composition consisting of one or more binding sites that preferentially bind to ADDLs.